Complete regression of metastatic tumors of the adult with antimitotic treatment.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002822:Choriocarcinoma / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006394:Hemangiosarcoma / Q000188:drug therapy; D006801:Humans; D007223:Infant; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008466:Mechlorethamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D011247:Pregnancy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy; D013899:Thoracic Neoplasms / Q000188:drug therapy; D013964:Thyroid Neoplasms / Q000188:drug therapy; D014228:Triaziquone / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000188:drug therapy; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003609:Dactinomycin; D008466:Mechlorethamine; D014747:Vinblastine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D014228:Triaziquone; D008727:Methotrexate